No Benefit to Adding Trastuzumab for HER2 Esophageal Cancer No Benefit to Adding Trastuzumab for HER2 Esophageal Cancer

In patients with HER2-overexpressing esophageal cancer, adding trastuzumab to neoadjuvant chemoradiation was not effective in a phase 3 trial.Reuters Health Information

Source: Medscape Gastroenterology Headlines - January 28, 2022 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news